Bloomberg Television
@markets·3.2M subscribers·95.6K videos
Copy-cats of weight-loss drugs Ozempic and Wegovy are hurting Novo Nordisk
Posted
August 1, 2025
Views
5,490
Likes
84
Comments
8
Engagement
August 1, 2025
5,490
84
8
1.68%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Episode Timeline
Every episode in order around the one you’re watching — click any card and the page flips straight to it.
1:42Now PlayingNovo Nordisk’s weight loss drugs Ozempic and Wegovy transformed the firm into a global pharmaceutical giant.
But four years after Wegovy’s US launch, the Danish drugmaker’s market value has plummeted.
@sanne_wass explains why
Novo’s copycat problem wasn’t supposed to last this long. It began when the company was unable to meet customer demand for its weight-loss drugs in the US, clearing the way for compounding pharmacies to step in. These pharmacies are allowed to make and sell cheaper copies of a medicine when brand-name drugs are in short supply, and their products don’t go have to go through the same rigorous approval process.
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
